Anuncio
Mercados españoles cerrados en 1 hr 21 mins

  • IBEX 35

    11.064,50
    +147,00 (+1,35%)
     

  • Euro Stoxx 50

    5.002,85
    +45,89 (+0,93%)
     

  • Dólar/Euro

    1,0783
    +0,0009 (+0,09%)
     

  • Petróleo Brent

    82,80
    -0,53 (-0,64%)
     

  • Oro

    2.326,90
    -4,30 (-0,18%)
     

  • Bitcoin EUR

    58.743,64
    -629,54 (-1,06%)
     

  • CMC Crypto 200

    1.310,87
    -54,25 (-3,97%)
     

  • DAX

    18.369,46
    +194,25 (+1,07%)
     

  • FTSE 100

    8.328,44
    +114,95 (+1,40%)
     

  • S&P 500

    5.189,17
    +8,43 (+0,16%)
     

  • Dow Jones

    38.954,03
    +101,76 (+0,26%)
     

  • Nasdaq

    16.345,57
    -3,68 (-0,02%)
     

  • Petróleo WTI

    77,98
    -0,50 (-0,64%)
     

  • EUR/GBP

    0,8584
    +0,0012 (+0,14%)
     

  • Plata

    27,65
    +0,04 (+0,13%)
     

  • NIKKEI 225

    38.835,10
    +599,03 (+1,57%)
     

Global Psychiatry Collaboration and Licensing Deals Directory, 2019-2024: Deal Trends, Leading Deals by Value, Most Active Dealmakers, Financials Terms, and More

Research and Markets
·3 min de lectura
Company Logo
Company Logo

Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Psychiatry Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of psychiatry deals from 2019 to 2024.

The report provides readers with the following key benefits:

  • Understand deal trends since 2019

  • Browse psychiatry collaboration and licensing deals

  • Benchmark analysis - identify market value of transactions

  • Financials terms - upfront, milestone, royalties

  • Directory of deals by company A-Z, therapy focus and technology type

  • Leading deals by value

  • Most active dealmakers

  • Identify assets and deal terms for each transaction

  • Access contract documents - insights into deal structures

  • Due diligence - assess suitability of your proposed deal terms for partner companies

  • Save hundreds of hours of research time

ANUNCIO

Report Scope

Psychiatry Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of psychiatry trends and structure of deals entered into by leading biopharma companies worldwide.

Psychiatry Collaboration and Licensing Deals includes:

  • Trends in psychiatry dealmaking in the biopharma industry

  • Overview of collaboration and licensing deal structure

  • Directory of psychiatry deal records covering pharmaceutical and biotechnology

  • The leading psychiatry deals by value

  • Most active psychiatry licensing dealmakers

In Psychiatry Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z

  • Headline value

  • Therapeutic area

  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Companies Featured (745 in Total)

  • 3Z

  • AbbVie

  • Ab Initio

  • ABL Bio

  • ABVC BioPharma

  • Acer Therapeutics

  • Ache

  • AC Immune

  • Actigraph

  • Aculys Pharma

  • Acumen Pharmaceuticals

  • AcuraStem

  • Adare Pharma Solutions

  • Addex Therapeutics

  • AffaMed Therapeutics

  • AgeX Therapeutics

  • AiBtl BioPharma

  • AiCure

  • Aiforia Technologies

  • AI Longevity

  • AimedBio

  • Aitia

  • Aker BioMarine

  • Akili Interactive Labs

  • Akome Biotech

  • Albert Einstein College of Medicine

  • Alchemab

  • Alector

  • Alex Therapeutics

  • Algernon Pharmaceuticals

  • Alkermes

  • Allied Corp

  • Alligator Bioscience

  • Alnylam Pharmaceuticals

  • Alpha Cognition

  • Altasciences

  • Alterity Therapeutics

  • Alternative Solutions

  • Altoida

  • Alto Neuroscience

  • Alvogen

  • Alzamend Neuro

  • Alzheimer's Association

  • Alzheimer's Drug Discovery Foundation

  • Alzheimer's Foundation of America

  • Alzheon

  • AlzProtect

  • Amerigen Pharmaceuticals

  • Amydis

  • ANANDA Scientific

  • and many more!

For more information about this report visit https://www.researchandmarkets.com/r/6rtz5b

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900